ALMS
AlumisBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Bulls can point to the Phase 3 psoriasis win, the favorable safety profile, the 4Q26 NDA path, and the 3Q26 SLE readout as a sequence of value-creating catalysts; secondary post-print coverage also says Chardan, Wells Fargo, and Guggenheim raised targets to $40, $51, and $34, respectively, after Q1 [#SEC-8K-2026-05-14] [#PR-EARNINGS-2026-05-29].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.0.
What can break
Psoriasis NDA timing and FDA feedback may slip; any CRL or label friction would hit the valuation hard.
Momentum
97
Value
41
Sentiment
48
Setup hits (3d)
— · Net —
AI TargetsBase $30.00 · Bull $45.00 · Bear $12.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net —
Target $40.10
Why
Momentum97 · Δ7d +0.0
Value41 · Δ7d -0.1
Sentiment48 · Δ7d -4.7
So what
Strength-led posture. Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
97
26% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+30.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
48
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.7
Δ21d
-10.3
Why this grade
Composite grade B. Momentum 96.7 / Value 41.1 / Sentiment 48.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$3.65B
Beta
-
Shares Out
127.49M
P/E (TTM) · Derived
-10.0
P/S (TTM)
39.22
P/FCF (TTM) · Derived
-7.45
Rev YoY
-90.0%
EPS YoY
-59.2%
Gross Margin
+58.1%
Op Margin
-1211.9%
Net Debt
-$271.67M
Current Ratio
7.51
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology